© 2022 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
June 21, 2022
David P. Hudesman, MD, and expert panelists provide insight on optimizing the sequencing of therapies in ulcerative colitis and determining when a change in treatment is needed.
Marla Dubinsky, MD, discusses the role of S1P receptor modulators and JAK inhibitors for the treatment of ulcerative colitis.
June 14, 2022
David P. Hudesman, MD, reviews the use of anti-integrin and anti-interleukin therapies for the management of ulcerative colitis.
Ellen J. Scherl, MD, comments on the limited role of mesalamine and steroids for moderate-to-severe ulcerative colitis treatment.
Joshua J. Joseph, MD: Managing CV Risk Factors in Patients with Type 2 Diabetes
Antirituximab Antibodies Detected in Patients with Pemphigus
Investigators Recommend 2 PROMs for Use in Acne Vulgaris